These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. Neuropathy Associated with Systemic Amyloidosis. Kaku M; Berk JL Semin Neurol; 2019 Oct; 39(5):578-588. PubMed ID: 31639841 [TBL] [Abstract][Full Text] [Related]
11. A novel TTR mutation (p.Ala65Val) underlying late-onset hereditary transthyretin (ATTRv) amyloidosis with mixed cardiac and neuropathic phenotype: a case report. Thimm A; Oubari S; Hoffmann J; Carpinteiro A; Papathanasiou M; Luedike P; Kessler L; Rischpler C; Röcken C; Diebold I; Rassaf T; Schmidt H; Kleinschnitz C; Hagenacker T BMC Neurol; 2022 Dec; 22(1):469. PubMed ID: 36494773 [TBL] [Abstract][Full Text] [Related]
12. Transthyretin Amyloidosis Presenting With Upper-Extremity Neuropathy and Paucity of Autonomic Impairment. Devarapalli S; Zhou DJ; Dyck PJB; Piccione EA J Clin Neuromuscul Dis; 2019 Jun; 20(4):207-209. PubMed ID: 31135624 [TBL] [Abstract][Full Text] [Related]
13. Three patients of transthyretin amyloidosis in a Japanese family with amyloidogenic transthyretin Thr49Ser (p.Thr69Ser) variant. Ikura H; Kitakata H; Endo J; Moriyama H; Sano M; Tsujikawa H; Sawano M; Masuda T; Ohki T; Ueda M; Kosaki K; Fukuda K Eur J Med Genet; 2022 Mar; 65(3):104451. PubMed ID: 35149236 [TBL] [Abstract][Full Text] [Related]
15. A description of variant transthyretin amyloidosis (ATTRv) stage 1 patients and asymptomatic carriers in Spain: the EMPATIa study. Galán Dávila L; Martinez Valle F; Buades Reinés J; Gonzalez-Moreno J; Losada López I; Sevilla T; Muñoz Beamud F; Bárcena Llona JE; Romero Acebal M; Setaro F; Primiano D; Tarilonte P Orphanet J Rare Dis; 2024 Sep; 19(1):323. PubMed ID: 39242501 [TBL] [Abstract][Full Text] [Related]
16. Red flags and adjusted suspicion index for distinguishing hereditary transthyretin amyloid polyneuropathy from idiopathic axonal polyneuropathy. Warendorf JK; van der Star GM; Dooijes D; Notermans NC; Vrancken AFJE Neurol Sci; 2023 Oct; 44(10):3679-3685. PubMed ID: 37266816 [TBL] [Abstract][Full Text] [Related]
17. Characteristics of Patients with Hereditary Transthyretin Amyloidosis-Polyneuropathy (ATTRv-PN) in NEURO-TTRansform, an Open-label Phase 3 Study of Eplontersen. Coelho T; Waddington Cruz M; Chao CC; Parman Y; Wixner J; Weiler M; Barroso FA; Dasgupta NR; Jung SW; Schneider E; Viney NJ; Dyck PJB; Ando Y; Gillmore JD; Khella S; Gertz MA; Obici L; Berk JL Neurol Ther; 2023 Feb; 12(1):267-287. PubMed ID: 36525140 [TBL] [Abstract][Full Text] [Related]
18. Hereditary Transthyretin Amyloidosis and the Impact of Classic and New Treatments on Kidney Function: A Review. Meléndrez-Balcázar E; Aranda-Vela K; Cervantes-Hernández A; López-Cureño S Am J Kidney Dis; 2024 Aug; 84(2):224-231. PubMed ID: 38484868 [TBL] [Abstract][Full Text] [Related]
19. Energetic characteristics of the new transthyretin variant A25T may explain its atypical central nervous system pathology. Sekijima Y; Hammarström P; Matsumura M; Shimizu Y; Iwata M; Tokuda T; Ikeda S; Kelly JW Lab Invest; 2003 Mar; 83(3):409-17. PubMed ID: 12649341 [TBL] [Abstract][Full Text] [Related]